Endometriosis Market Report 2026

The endometriosis market size has grown strongly in recent years. It will grow from $1.54 billion in 2025 to $1.68 billion in 2026 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to underdiagnosis of endometriosis, growth in gynecological consultations, rising infertility cases, hormonal therapy adoption, pain management demand.

The endometriosis market size is expected to see strong growth in the next few years. It will grow to $2.44 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to early screening initiatives, improved diagnostic accuracy, personalized treatment approaches, women’s health advocacy, expansion of specialty care. Major trends in the forecast period include rising awareness of chronic pelvic pain, increased diagnosis of fertility-related disorders, growing use of hormonal therapies, expansion of specialty gynecology centers, focus on long-term disease management.

The rising incidence of ovarian cancer is expected to drive the growth of the endometriosis market in the coming years. Ovarian cancer is a malignancy that originates in the ovaries, which are female reproductive organs responsible for egg production and the secretion of hormones such as estrogen and progesterone. Endometriosis is linked to a higher risk of developing epithelial ovarian cancer, particularly the endometrioid and clear cell subtypes, which are often associated with elevated estrogen levels that may increase the likelihood of ovarian cancer development. For example, in January 2023, the American Cancer Society, a US-based professional organization, projected that approximately 19,710 new cases of ovarian cancer would be diagnosed among women in the United States in 2023. In addition, data from the Ovarian Cancer Research Alliance, a US-based not-for-profit organization, indicated that ovarian cancer resulted in 12,810 deaths in 2022, rising to 13,270 deaths in 2023. Therefore, the growing incidence of ovarian cancer is contributing to the expansion of the endometriosis market.

Key players in the endometriosis market are focusing on the development of innovative solutions, including non-invasive diagnostic assays, to enhance early detection and improve patient management. Non-invasive diagnostic assays are tests that identify or monitor disease without the need for surgical procedures or invasive instruments, often relying on samples such as blood, urine, saliva, or imaging data. For instance, in July 2025, Kephera Diagnostics LLC, a US-based diagnostic laboratory, introduced EndomTest, an advanced blood-based diagnostic test for endometriosis. EndomTest is a laboratory-developed assay that evaluates a patient’s serum sample for biomarkers such as brain-derived neurotrophic factor (BDNF) and cancer antigen 125 (CA125), and integrates these results with selected clinical variables through a proprietary diagnostic algorithm to generate a positive or negative “rule-in” indication for endometriosis. Notable features of the test include a non-surgical sample collection method requiring only a blood draw, reported high specificity approaching 100% for disease identification, and broad clinical applicability for women experiencing pelvic pain, heavy menstrual bleeding, infertility, or dyspareunia.

In January 2024, Hera Biotech Inc., a US-based women’s health diagnostics company, acquired the endometriosis diagnostic assets and associated intellectual property of Scailyte for an undisclosed amount. Through this acquisition, Hera Biotech aims to accelerate the development of its next-generation endometriosis diagnostic solutions by incorporating Scailyte’s single-cell data analytics and biomarker discovery platform. Scailyte AG is a Switzerland-based biotechnology company that specializes in AI-driven single-cell analysis to support precision diagnostics.

Major companies operating in the endometriosis market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck and Co. Inc., Abbvie Inc., Bayer AG, GlaxoSmithKline plc, Abbott Laboratories, Eli Lilly and Company, Mylan N.V., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, Cadila Pharmaceuticals Ltd., Gedeon Richter plc, Torrent Pharmaceuticals Ltd., Ferring Pharmaceuticals, Kissei Pharmaceutical Co. Ltd., Sanofi India Ltd., Repros Therapeutics Inc., Myovant Sciences Ltd., Takeda Pharmaceutical Company Limited, ObsEva SA, Gesynta Pharma AB, Zydus Healthcare Limited.

North America was the largest region in the endometriosis market in 2025. The regions covered in the endometriosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the endometriosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the endometriosis market by increasing costs of imported hormonal drugs, diagnostic equipment, and surgical tools. Hospitals and specialty centers in North America and Europe are most affected due to reliance on imported therapies. These tariffs raise treatment costs by increasing expenses for long-term hormonal management and surgical intervention, affecting patient access to care. However, they encourage domestic pharmaceutical manufacturing, supporting localized production of hormonal therapies.

The endometriosis market research report is one of a series of new reports that provides endometriosis market statistics, including endometriosis industry global market size, regional shares, competitors with a endometriosis market share, detailed endometriosis market segments, market trends and opportunities, and any further data you may need to thrive in the endometriosis industry. This endometriosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Endometriosis is a long-term medical condition in which tissue resembling the uterine lining (endometrium) develops outside the uterus. This condition can lead to intense pelvic pain and may reduce the ability to conceive. It can have a substantial effect on an individual’s quality of life and reproductive health.

The primary types of endometriosis include superficial peritoneal lesions, endometrioma, deeply infiltrating endometriosis, and others. A superficial peritoneal lesion is a particular form of abnormal tissue growth observed in endometriosis cases. Treatment options include hormonal therapies and pain management approaches. The condition is managed using various medications such as oral contraceptives, progestins, nonsteroidal anti-inflammatory drugs (NSAIDs), gonadotropin-releasing hormone (GnRH) analogs, levonorgestrel-releasing intrauterine devices (LNG-IUDs), and others, which are utilized across different end users including hospitals, homecare settings, specialty centers, and others.

The endometriosis market consists of revenues earned by entities by providing services such as laparoscopy, nutritional counseling, physical therapy, diagnostic laparoscopy, fertility treatment, surgical interventions and complementary therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The endometriosis market also includes sales of birth control pills, patches and vaginal rings. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.